Nasa Captures 'Space Horse' To Mark Hubble's 23rd Birthday

1a Supernova Remnant

This undated photo shows a classic type 1a supernova remnant. Researchers Saul Perlmutter and Adam Riess of the United States and US-Australian Brian Schmidt won the 2011 Nobel Physics Prize on October 4, 2011 for their research on supernovae.

The silhouette of the space shuttle Endeavour appears over Earth's colorful horizon in this image photographed by an Expedition 22 crew member on Feb. 9, 2010.

"These tidal tails are thin, elongated streams of gas, dust and stars that extend away from a galaxy into space. They occur when galaxies gravitationally interact with one another, and material is sheared from the outer edges of each body and flung out into space in opposite directions, forming two tails. They almost always appear curved, so when they are seen to be relatively straight, as in this image, it is clear that we are viewing the galaxies side-on."

This image provided by NASA shows the Solar Dynamic Observatory's ultra-high-definition view of Venus, black dot at top center, passing in front of the sun on Tuesday, June 5, 2012. The next transit of Venus won't be for another 105 years. (NASA/Solar Dynamic Observatory/AP)

This image provided by NASA shows the image captured by Hinode on June 5, 2012 of the transit of Venus -- the last instance of this rare phenomenon until 2117. Hinode is a joint JAXA/NASA mission to study the connections of the sun's surface magnetism, primarily in and around sunspots. NASA's Marshall Space Flight Center in Huntsville, Ala., manages Hinode. The Smithsonian Astrophysical Observatory in Cambridge, Mass., is the lead U.S. investigator for the X-ray Telescope. (JAXA NASA/AP)

A bubbling cauldron of star birth is highlighted in this image from NASA's Spitzer Space Telescope. Infrared light that we can't see with our eyes has been color-coded, such that the shortest wavelengths are shown in blue and the longest in red. The middle wavelength range is green. Massive stars have blown bubbles, or cavities, in the dust and gas--a violent process that triggers both the death and birth of stars. The brightest, yellow-white regions are warm centers of star formation. The green shows tendrils of dust, and red indicates other types of dust that may be cooler, in addition to ionized gas from nearby massive stars.

This image shows the Large Magellanic Cloud galaxy in infrared light as seen by the Herschel Space Observatory, a European Space Agency-led mission with important NASA contributions, and NASA's Spitzer Space Telescope. In the instruments' combined data, this nearby dwarf galaxy looks like a fiery, circular explosion. Rather than fire, however, those ribbons are actually giant ripples of dust spanning tens or hundreds of light-years. Significant fields of star formation are noticeable in the center, just left of center and at right. The brightest center-left region is called 30 Doradus, or the Tarantula Nebula, for its appearance in visible light.

This enhanced-color image shows sand dunes trapped in an impact crater in Noachis Terra, Mars. Dunes and sand ripples of various shapes and sizes display the natural beauty created by physical processes. The area covered in the image is about six-tenths of a mile (1 kilometer) across. Sand dunes are among the most widespread wind-formed features on Mars. Their distribution and shapes are affected by changes in wind direction and wind strength. Patterns of dune erosion and deposition provide insight into the sedimentary history of the surrounding terrain.

This image obtained by the framing camera on NASA's Dawn spacecraft shows the south pole of the giant asteroid Vesta. Scientists are discussing whether the circular structure that covers most of this image originated by a collision with another asteroid, or by internal processes early in the asteroid's history. Images in higher resolution from Dawn's lowered orbit might help answer that question. The image was recorded with the framing camera aboard NASA's Dawn spacecraft from a distance of about 1,700 miles (2,700 kilometers). The image resolution is about 260 meters per pixel.

View post:

Nasa Captures 'Space Horse' To Mark Hubble's 23rd Birthday

PhoneSats in Space: Tiny NASA Satellites Have Smartphone Brains

A trio of small NASA satellites flying around Earth may give new meaning to the phrase, "Can you hear me now?"

Three off-the-shelf smartphones were just launched to space as part of a NASA initiative to make powerful satellites cheaper.

The trio of PhoneSats aptly named Alexander, Graham and Bell were successfully launched into orbit Sunday (April 21) during the inaugural test flight of Orbital Sciences Corp's Antares rocket. The new private rocket launched from NASA's Wallops Flight Facility located on Wallops Island along Virginia's Eastern Shore.

NASA has confirmed that, all three of the coffee-cup-size PhoneSats are now in orbit and beaming back information.

"We expect them to stay up for about 2 weeks, but actually our mission with these is only going to last a few days," Andrew Petro, program executive for NASA's Small Spacecraft Technology Program told SPACE.com. "This is a test basically to see how they form." [See How PhoneSats Work (Video)]

The phones will basically function as the brain of the satellite. The three 3 pound (1.4 kilogram) cubes won't be used for communication purposes, Petro said. In fact, the phones cannot send or receive calls or text messages.

"The idea was to use that [the phone] as the brain for the satellite," Petro said. "What you end up with is a relatively inexpensive."

While most satellites can cost more than $1 million, the three PhoneSats cost $3,500 to $7,000 each.

Alexander and Graham both PhoneSat 1.0s are battery-powered and carry a Nexus One smartphone running Goggle's Android operating system on board. These kinds of PhoneSats were exposed to extreme conditions in 2011, according to NASA officials. The tiny satellite was tested during sub-orbital rocket flights, from high altitude balloons and on vibration and shock tables.

Bell is a more advanced kind of cubesat. The PhoneSat 2.0 built around a Nexus S smartphone running on Android comes equipped with solar panels and a two-way radio that allows engineers to control the satellite from the ground. Its solar panels could make longer missions using the satellite possible in the future, according to a statement from NASA.

Go here to read the rest:

PhoneSats in Space: Tiny NASA Satellites Have Smartphone Brains

NASA Must Pay for Plutonium Production to Fuel Deep-Space Probes

NASA will now foot the entire bill for the United States' production of plutonium-238 spacecraft fuel, which recently started up again for the first time in a quarter-century.

The space agency had been splitting costs for the reboot with the U.S. Department of Energy, which actually produces plutonium-238. But NASA is the only projected user of the stuff, so the arrangement changed in the White House's federal budget request for 2014, which was unveiled earlier this month.

"Since the [Obama] Administration has a 'user pays' philosophy, we are now in a position to pay for basically the entire enterprise, including the base infrastructure at DOE," NASA chief financial officer Beth Robinson said in an April 10 press conference. "We'll be partnering with DOE in the next couple of months to figure out how to best do this, and how to streamline the program to produce plutonium-238."[Nuclear Generators Power NASA Probes (Infographic)]

Plutonium-238 is not a bombmaking material, but it is radioactive, emitting heat that can be converted to electricity using a device called a radioisotope thermoelectric generator. For decades, RTGs have powered NASA probes to destinations in deep space, where sunlight is too weak and dispersed to be of much use to a robot.

For example, the agency's twin Voyager spacecraft, which are knocking on the door of interstellar space, are both RTG-powered. So is the Mars rover Curiosity, whose observations recently helped scientists determine that the Red Planet could once have supported microbial life.

The DOE stopped producing Pu-238 in 1988, after which NASA began sourcing the fuel from Russia. But the agency received its last Russian shipment in 2010, and supplies have been dwindling ever since, worrying many scientists and space-exploration advocates.

So NASA and the DOE have been working together on a Pu-238 restart, which officials from both agencies have estimated will cost between $75 million and $90 million over five years.

This effort has made significant progress. NASA officials announced last month that researchers at the DOE's Oak Ridge National Laboratory in Tennessee had irradiated targets of neptunium-237 with neutrons, successfully generating small amounts of plutonium-238 the nation's first in 25 years.

Scaling up from these early test activities shouldn't be too much of a chore, officials said.

"By optimizing the production process, it is estimated that 1.5 to 2 kilograms [3.3 to 4.4 pounds] per year will be produced by 2018. This amount will be enough to meet NASA's projected needs for future planetary missions. The Science budget request fully funds this requirement," NASA officials wrote in the agency's 650-page explanation of its 2014 budget request.

Excerpt from:

NASA Must Pay for Plutonium Production to Fuel Deep-Space Probes

Six nanotechnology courses set at Ivy Tech

SOUTH BEND -- Ivy Tech Community College in South Bend will offer a special summer session of nanotechnology courses from May 20 through Aug. 10.

The courses will be taught at Ivy Tech, in collaboration with Penn State University's Center for Nanotochnology Education & Utilization and the University of Notre Dame.

There will be an open house from 9 a.m. to 5 p.m. Friday to provide information about the summer program. The open house, which is free and open to the general public, will be in Room 1300 at the Ivy Tech campus, 220 Dean Johnson Blvd. Nanotechnology faculty and admissions staff will be available to answer questions, demonstrate equipment and assist prospective students with enrollment.

Ivy Tech in South Bend is the only Ivy Tech campus in the state that offers an associate degree program in nanotechnology.

The summer program will consist of six nanotechnology courses presented sequentially in two-week modules. All courses are three credit hours, and will meet from 8 a.m. to 3 p.m. weekdays, each for a total of two weeks. Each student who completes the program will be awarded a certificate of completion by Penn State's Center for Nanotechnology Education & Utilization.

Housing for students who live outside the area will be available through a partnership with Indiana University South Bend.

To make a reservation for the open house or for more information about the nanotechnology program, contact Sam Agdasi at aaghdasi@ivytech.edu or by phone at 574-289-7001, ext. 6355.

See the original post here:

Six nanotechnology courses set at Ivy Tech

A KEY TO REGENERATIVE MEDICINE: Discovery of a new adult stem cell with special properties – Video


A KEY TO REGENERATIVE MEDICINE: Discovery of a new adult stem cell with special properties
Learn about the exciting discovery that could revolutionize regenerative medicine by providing a source to produce organs derived from a patient #39;s own stem c...

By: YourekaScience

View original post here:

A KEY TO REGENERATIVE MEDICINE: Discovery of a new adult stem cell with special properties - Video

Holistic Medicine: A Philosophy of Holistic Medical Practice with Dr. Stanley Lang – Video


Holistic Medicine: A Philosophy of Holistic Medical Practice with Dr. Stanley Lang
Holistic Medicine: An Philosophy of Holistic Medical Practice with Dr. Stanley Lang http://www.StanleyLang.com Dr. Stanley Lang, MD, shares his insights on "holisti...

By: Justin West

See the rest here:

Holistic Medicine: A Philosophy of Holistic Medical Practice with Dr. Stanley Lang - Video

North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F …

NEW YORK, April 22, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) Forecast to 2017 http://www.reportlinker.com/p01163147/North-American-Nuclear-Medicine/Radiopharmaceuticals--Stable-Isotopes-Market-%5BSPECT/PET-Radioisotopes-Technetium-F-18%5D-%5BBeta/Alpha-Radiation-Therapy-I131-Y-90%5D-%5BApplications-Cancer/Oncology-Cardiac%5D--Deuterium-C-13---Forecast-to-2017 .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

The North American radiopharmaceuticals market was valued at $1.9 billion in 2012 and is poised to reach $2.7 billion by 2017 at a CAGR of 7.2%.

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as North America between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 in Canada is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects; radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

The U.S. is the dominant market for diagnostic radioisotopes with more than 80% share. The U.S. is the largest consumer market for radiopharmaceuticals in North America, while Canada is one of the largest producers of Tc-99m. Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Triad Isotopes, Inc. (U.S.).

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) and Sigma Aldrich - in 2012; they jointly contributed more than 90% to the North American revenue.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (U.S. and Canada) to provide in-depth information on the country basis.

North American Radiopharmaceuticals Market

Read this article:

North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F ...

40 percent of parents give young kids medicine they shouldn't

Four in 10 U.S. parents give children age 4 and younger cough/cold medicine that is not recommended for young children, researchers say.

License photo

ANN ARBOR, Mich., April 23 (UPI) -- Four in 10 U.S. parents give children age 4 and younger cough/cold medicine that is not recommended for young children, researchers say.

Dr. Matthew M. Davis, director of the C.S. Mott Children's Hospital National Poll on Children's Health, said children can get five to 10 colds each year, so adults often turn to over-the-counter cough and cold medicines.

However, a University of Michigan C.S. Mott Children's Hospital National Poll showed more than 40 percent of parents reported giving their children age 4 and younger cough medicine and multi-symptom cough and cold medicine. Twenty-five percent gave decongestants.

In 2008, the U.S. Food and Drug Administration issued an advisory that over-the-counter medicines -- cough medicine, multi-symptom cough and cold medicine and decongestants -- should not be given to small children.

They have not been proven effective for young children and may cause serious side effects, said Davis.

"These products don't reduce the time the infection will lasts and misuse could lead to serious harm," Davis said in a statement. "What can be confusing is that often these products are labeled prominently as 'children's' medications.'"

However, details are often on the back of the box, in small print. "That's where parents and caregivers can find instructions that they should not be used in children age 4 and younger," Davis said.

The side effects from use of cough and cold medicines in young children may include allergic reactions, increased or uneven heart rate, drowsiness or sleeplessness, slow and shallow breathing, confusion or hallucinations, convulsions, nausea and constipation, Davis said.

More:

40 percent of parents give young kids medicine they shouldn't

European Nuclear Medicine / Radiopharmaceuticals Market – Global Trends & Forecasts to 2017

DUBLIN, April 23, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecas" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The European radioisotopes market was valued at $1.1 billion in 2012 and is poised to reach $1.6 billion in 2017 at a CAGR of 6.8%.

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, and other developed regions between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 and OSIRIS in France in 2018 is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the European scenario.

Please click here to view a sample of this report.

Key Topics Covered:

1 Key Take-Aways

Excerpt from:

European Nuclear Medicine / Radiopharmaceuticals Market - Global Trends & Forecasts to 2017

Life Technologies' Ion Proton(TM) to Power Stratified Medicine Scotland Innovation Centre

- Innovation Centre's ambitious approach to treatment of disease to dramatically improve patient outcomes whilst reducing overall healthcare costs.

GLASGOW, Scotland, April 23, 2013 /PRNewswire/ --

Life Technologies( http://www.lifetechnologies.com/us/en/home.html ) Corporation (LIFE) today announces that it is a lead commercial partner along with Aridhia,( http://www.aridhia.com ) a bio-medical informatics company, in the Stratified Medicine Scotland Innovation Centre (SMS-IC). The Ion Proton( http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Sequencing/Semiconductor-Sequencing/proton.html )(TM) sequencing platform will be the primary tool to drive discovery and genetic analysis as SMS-IC aspires to be a world-class centre of research, innovation and commercialisation in stratified medicine. The SMC-IC is a unique collaboration bringing together excellence in the academic, industrial and NHS( http://www.show.scot.nhs.uk/introduction.aspx ) communities to create an infrastructure that will act as a springboard to allow Scotland to be at the forefront of the field.

The First Minister of Scotland, Alex Salmond said: "Scotland has always been a world leader in innovation and this new funding for the Stratified Medicine Scotland Innovation Centre reinforces the Scottish Government's commitment to the Life Sciences securing Scotland's place as a world leader in innovative health technology. The pioneering research carried out by the innovation centres will not only improve the healthcare of patients but also, by way of the unique advanced process of diagnosis, could potentially save lives."

"The Stratified Medicine Scotland Innovation Centre is a ground breaking project that represents a real opportunity to change the way healthcare will be practiced," said Peter Silvester, President Europe, Middle East & Africa of Life Technologies( http://www.lifetechnologies.com/us/en/home.html ). "Life Technologies will provide facilities and the genetic analysis platform with its semiconductor based, Ion Proton( http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Sequencing/Semiconductor-Sequencing/proton.html )(TM) DNA sequencing technology, at a speed, accuracy and cost that would have been impossible just a few months ago. The vision for this project is to combine an individual's detailed genomic data with more traditional patient information to enable faster, more accurate and effective clinical decisions. This is an inflection point in the history of medical research, and there is much more to come."

Stratified medicine is recognised as a key strategic approach to the future diagnosis and treatment of disease and depends critically upon information; the integration of existing data sets to form a comprehensive 'personal' healthcare record and the generation of new data describing patient characteristics - genotype and phenotype - to permit 'stratification.'

Scotland's past investment in electronic health records (EHRs) and translational medicine research, coupled with a vibrant healthcare technology industry, positions Scotland as the location to drive forward the stratified medicine agenda globally. The aim of SMS-IC is to prove the principle of stratified clinical trials and in 2013 it will begin a series of exemplar projects which link patient phenotype, genotypic and other data types enabling precision targeting of populations for clinical trials. Although the Ion Proton( http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Sequencing/Semiconductor-Sequencing/proton.html )(TM)platform is currently for Research Use Only, the ultimate aim is to take stratified clinical trial models from concept to clinical practice. SMS-IC will run a competition to identify suitable projects and applications are invited from interested parties.

A semiconductor chip is at the heart of the Ion Proton's technology. Instead of relying on light-based technology and cameras to capture images of DNA sequences, the Ion Proton( http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Sequencing/Semiconductor-Sequencing/proton.html )(TM) System translates chemical information into digital data. The chip enables sequencing to be performed on a massively parallel format, drastically accelerating the sequencing process.

The Ion Proton( http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Sequencing/Semiconductor-Sequencing/proton.html )(TM)is For Research Use Only, not intended for diagnostic purposes.

About Life Technologies

Read more here:

Life Technologies' Ion Proton(TM) to Power Stratified Medicine Scotland Innovation Centre

China Chinese Patent Medicine Industry Report, 2012-2015

NEW YORK, April 22, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

China Chinese Patent Medicine Industry Report, 2012-2015

http://www.reportlinker.com/p0361703/China-Chinese-Patent-Medicine-Industry-Report-2012-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

In recent years, China's Chinese patent medicine industry has been running in good condition, with the revenue increasing from RMB 142 billion in 2008 to RMB 360 billion in 2012 at a CAGR of 26.2%. Over the same period, the total profit maintained a CAGR of 26.6%, and the gross margin remained higher than the average level of the overall pharmaceutical industry.

In succession to the Opinions on Promoting the Development of Traditional Chinese Medicine Services and Trade, the Twelfth Five-Year Plan on the Development of Traditional Chinese Medicine and other favorable policies, the new National Essential Drugs List published in March 2013 increased the number of Chinese patent medicine from 102 in 2009 to 203, and the proportion in total quantity from 33% to 39%. As a result, China's Chinese patent medicine market demand is expected to grow rapidly in the next five years.

Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases, tumor diseases, respiratory system diseases, musculoskeletal diseases and digestive system diseases are top five categories of Chinese patent medicine for hospitals in China. The Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases occupies the largest market share, which remained at around 37% in 2006-2012. Outstanding enterprises producing Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases include Shandong Buchang Pharma (products include Guanxin Shutong Capsule and Naoxinshu Oral Solution), Tianjin Tasly Group (products include Compound Danshen Dripping Pills and Yangxue Qingnao Granule), J Pharmaceutical (products include Mailuoning Injection and Mailuoning Oral Solution), Shijiazhuang Yiling Pharmaceutical (products include Tongxinluo Capsule and Shensong Yangxin Capsule), etc.

As China's Chinese patent medicine is gaining international recognition, coupled with the incentive from high profit (the operating margin is generally above 70%) and the development bottleneck of the chemical pharmaceutical industry, foreign enterprises and institutions such as Novartis, Merck, Johnson & Johnson, GSK have set foot in the Chinese patent medicine market through joint ventures and wholly-owned subsidiaries. For example, in early 2013, GSK announced to carry out drug development trying to use traditional Chinese medicinal ingredients in China.

China Chinese Patent Medicine Industry Report, 2012-2015 of ResearchInChina mainly includes the following contents:

Industrial policies, development status, regional market, import and export, development trend of China's Chinese patent medicine industry; Development status of the raw material market of China's Chinese patent medicine industry as well as the development status and import & export of China's plant extracts; China's Chinese patent medicine market segments, including Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases, tumor diseases, respiratory system diseases, etc.; Operation, revenue structure, gross margin and profit forecast of China's 10 major Chinese patent medicine production enterprises.

Table of Contents

Excerpt from:

China Chinese Patent Medicine Industry Report, 2012-2015

Life Technologies' Ion Protonâ„¢ to Power Stratified Medicine Scotland Innovation Centre

Innovation Centre's ambitious approach to treatment of disease to dramatically improve patient outcomes whilst reducing overall healthcare costs.

GLASGOW , Scotland, April 23, 2013 /CNW/ - Life Technologies Corporation (LIFE) today announces that it is a lead commercial partner along with Aridhia, a bio-medical informatics company, in the Stratified Medicine Scotland Innovation Centre (SMS-IC). The Ion Proton sequencing platform will be the primary tool to drive discovery and genetic analysis as SMS-IC aspires to be a world-class centre of research, innovation and commercialisation in stratified medicine. The SMC-IC is a unique collaboration bringing together excellence in the academic, industrial and NHS communities to create an infrastructure that will act as a springboard to allow Scotland to be at the forefront of the field.

The First Minister of Scotland, Alex Salmond said: "Scotland has always been a world leader in innovation and this new funding for the Stratified Medicine Scotland Innovation Centre reinforces the Scottish Government's commitment to the Life Sciences securing Scotland's place as a world leader in innovative health technology. The pioneering research carried out by the innovation centres will not only improve the healthcare of patients but also, by way of the unique advanced process of diagnosis, could potentially save lives."

"The Stratified Medicine Scotland Innovation Centre is a ground breaking project that represents a real opportunity to change the way healthcare will be practiced," said Peter Silvester , President Europe , Middle East & Africa of Life Technologies. "Life Technologies will provide facilities and the genetic analysis platform with its semiconductor based, Ion Proton DNA sequencing technology, at a speed, accuracy and cost that would have been impossible just a few months ago. The vision for this project is to combine an individual's detailed genomic data with more traditional patient information to enable faster, more accurate and effective clinical decisions. This is an inflection point in the history of medical research, and there is much more to come."

Stratified medicine is recognised as a key strategic approach to the future diagnosis and treatment of disease and depends critically upon information; the integration of existing data sets to form a comprehensive 'personal' healthcare record and the generation of new data describing patient characteristics - genotype and phenotype - to permit 'stratification.'

Scotland's past investment in electronic health records (EHRs) and translational medicine research, coupled with a vibrant healthcare technology industry, positions Scotland as the location to drive forward the stratified medicine agenda globally. The aim of SMS-IC is to prove the principle of stratified clinical trials and in 2013 it will begin a series of exemplar projects which link patient phenotype, genotypic and other data types enabling precision targeting of populations for clinical trials. Although the Ion Protonplatform is currently for Research Use Only, the ultimate aim is to take stratified clinical trial models from concept to clinical practice. SMS-IC will run a competition to identify suitable projects and applications are invited from interested parties.

A semiconductor chip is at the heart of the Ion Proton's technology. Instead of relying on light-based technology and cameras to capture images of DNA sequences, the Ion Proton System translates chemical information into digital data. The chip enables sequencing to be performed on a massively parallel format, drastically accelerating the sequencing process.

The Ion Protonis For Research Use Only, not intended for diagnostic purposes.

About Life Technologies Life Technologies Corporation (LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions are secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Originally posted here:

Life Technologies' Ion Protonâ„¢ to Power Stratified Medicine Scotland Innovation Centre

Modernizing Medicine Is Unanimously Voted In as a Member of the Exclusive HIMSS EHR Association

ORLANDO, FL--(Marketwired - Apr 22, 2013) - Partnerships in Clinical Trials -- Modernizing Medicine, the creator of the Electronic Medical Assistant (EMA), a cloud-based, specialty-specific electronic medical records (EMR) system, today announced that it has been unanimously voted in as a member of the excusive HIMSS Electronic Health Record (EHR) Association, a trade association of EHR companies addressing national efforts to create interoperable EHRs in hospital and ambulatory care settings.

"We welcome Modernizing Medicine to the team and look forward to working with them," said Mickey McGlynn, EHR Association Chair and Senior Director of Strategy and Operations for Siemens Healthcare."Every new member brings fresh perspectives and energy to the work we do in representing the industry and our customers on a variety of impactful issues."

Members of the EHR Association work together to accelerate health IT (HIT) adoption, advance interoperability and provide education to all healthcare industry stakeholders including standards organizations and policymakers.Members share the belief that widespread EHR adoption will help improve the quality of patient care and the productivity of the US healthcare system. The EHR Association has been providing testimony, comments and education to federal legislators and policymakers since its inception in 2004. Along with codifying ONC, establishing financial incentives through the meaningful use program, and support for HIT training programs, the organization's ongoing efforts established the basis for broader collaboration.

"Modernizing Medicine is honored to be a member of this prestigious organization," said Charles L. "Chuck" Brodsky, Executive Vice President of Business Development. "Our team is looking forward to making contributions to improvements in patient care and clinical research with our colleagues in the industry."

In just over three years, Modernizing Medicine has captured more than 14% of the U.S. dermatology market with more than 2,400 providers using EMA daily in their practices.Earlier this year, Modernizing Medicine introduced the EMA Network featuring EMA Outcomes and EMA Grand Rounds.EMA Outcomes visualizes and trends patient information over time to provide a snapshot of the patient's chart without having to flip through it, and EMA Grand Rounds instantaneously contextualizes treatment patterns at the point of care across millions of patient encounters. The EMA Network supports the EHR Association's mission of providing the healthcare industry with optimal patient care and productivity. To learn more, visit Modernizing Medicine booth #418 at the Partnerships in Clinical Trials Conference this week.

About Modernizing MedicineModernizing Medicine is delivering the next generation of electronic medical records (EMR) technology for the healthcare industry. Our product, Electronic Medical Assistant (EMA), is a cloud-based, specialty-specific EMR system with a massive library of built-in medical content, designed to save physicians time. Available as a native iPad application or from any web-enabled Mac or PC, EMA adapts to each provider's unique style of practice and is designed to interface with hundreds of different practice management systems. Today, Modernizing Medicine provides specialty-specific offerings for the dermatology, ophthalmology, optometry, orthopedics and plastic and cosmetic surgery markets, and to more than 800 physician practices across the country.In 2013 Modernizing Medicine was listed at No. 47 on FORBES annual ranking of America's Most Promising Companies.

About the EHR AssociationEstablished in 2004, the Electronic Health Record (EHR) Association is comprised of more than 40 companies that supply the vast majority of operational EHRs to physicians' practices and hospitals across the United States.The EHR Association operates on the premise that the rapid, widespread adoption of EHRs will help improve the quality of patient care as well as the productivity and sustainability of the healthcare system as a key enabler of healthcare transformation.The EHR Association and its members are committed to supporting safe healthcare delivery, fostering continued innovation, and operating with high integrity in the market for our users and their patients and families.For more information, visit http://www.himssehra.org.

The EHR Association is a partner of the Health Information Systems Management Society (HIMSS).

Follow this link:

Modernizing Medicine Is Unanimously Voted In as a Member of the Exclusive HIMSS EHR Association

Ross University School of Medicine Establishes Education Agreement with Vanguard MacNeal Hospital

MIRAMAR, Fla.--(BUSINESS WIRE)--

Ross University School of Medicine (RUSM) announced an agreement with Vanguard MacNeal Hospital in Berwyn, Ill. which enables RUSM students to perform clinical training in the Chicago-area teaching hospital.

RUSM students in their third year of medical school will be able to train in surgery and internal medicine at MacNeal. The MacNeal residency programs in surgery and internal medicine are approved by the Accreditation Council for Graduate Medical Education (ACGME), which is responsible for accrediting graduate medical education training programs.

MacNeal Hospital is part of a network that serves the healthcare needs of more than one million in the Chicago suburbs. Their strong medical training program offers our students the opportunity to be exposed to leading-edge advances in patient care in a hospital with a real commitment to mentoring medical students, said Joseph Flaherty, MD, dean and chancellor at RUSM.

Were looking forward to this new partnership with Ross University School of Medicine, said Diana Viravec, MD, Chief Academic Officer for Vanguard Health Chicago. We think this will be a great opportunity for RUSM students to learn from a team of physicians and other clinical staff dedicated to training the next generation of doctors in the best practices of patient care.

RUSM students begin their journey to become physicians on the Schools campus in Dominica, located in the West Indies. There the students complete a rigorous, accelerated study in the basic sciences. The campus features a cutting-edge anatomy and medical imaging laboratory, as well as a simulation center where students begin to develop clinical skills. Students complete their core and elective clinical rotations in U.S. affiliates like MacNeal.

In recent months, RUSM has begun or expanded clinical education affiliations with a number of highly regarded teaching hospitals. Last year, RUSM entered into a 10-year affiliation with Kern Medical Center in Bakersfield, Calif. to offer about 100 core clinical rotation slots annually for RUSM students. That partnership is the largest clinical affiliation in RUSMs history. RUSM has also added rotations recently at Atlanta Medical Center, Memorial Regional Hospital (South Florida), California Hospital Medical Center (Los Angeles, Calif.), and Cleveland Clinic Florida (Weston, Fla.).

About MacNeal Hospital

MacNeal Hospital is a Joint Commission-accredited, 427-bed teaching hospital located in the western suburb of Berwyn. Staffed with over 500 physicians, the hospital offers a comprehensive array of advanced inpatient and outpatient medical, surgical and psychiatric services. Part of Vanguard Health Systems, Chicago Market, MacNeal offers 50 medical specialties, which offer technologically advanced diagnostics and effective treatments in a convenient community setting. Visit http://www.macneal.com for more information.

About Ross University School of Medicine

Read more:

Ross University School of Medicine Establishes Education Agreement with Vanguard MacNeal Hospital

Harvard Medical School alcohol prevention speaker – stroke symptoms signs – Video


Harvard Medical School alcohol prevention speaker - stroke symptoms signs
Harvard Medical School alcohol prevention speaker - stroke symptoms signs http://www.PaulFDavis.com has touched 70 countries w life-changing messages (info@P...

By: greatawakening

Read the original post:

Harvard Medical School alcohol prevention speaker - stroke symptoms signs - Video